Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Rapid Micro Biosystems's Revenue for the
three
months ended in Mar. 2026 was $8.00 Mil. Rapid Micro Biosystems's Total Assets for the quarter that ended in Mar. 2026 was $68.61 Mil. Therefore, Rapid Micro Biosystems's Asset Turnover for the quarter that ended in Mar. 2026 was 0.12.
Asset Turnover is linked to ROE % through Du Pont Formula. Rapid Micro Biosystems's annualizedROE % for the quarter that ended in Mar. 2026 was -213.04%. It is also linked to ROA % through Du Pont Formula. Rapid Micro Biosystems's annualizedROA % for the quarter that ended in Mar. 2026 was -83.23%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
Rapid Micro Biosystems's annulizedROA % for the quarter that ended in Mar. 2026 is
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
Rapid Micro Biosystems Asset Turnover Related Terms
Rapid Micro Biosystems Asset Turnover Historical Data
* Premium members only.
The historical data trend for Rapid Micro Biosystems's Asset Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RPID vs ZOMDF, STIM, OM: Asset Turnover Comparison
For the Medical Devices subindustry, Rapid Micro Biosystems's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapid Micro Biosystems Asset Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Rapid Micro Biosystems's Asset Turnover distribution charts can be found below:
* The bar in red indicates where Rapid Micro Biosystems's Asset Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
Rapid Micro Biosystems (RPID) has a Asset Turnover of 0.12 as of Mar. 2026. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Rapid Micro Biosystems and its competitors.
Is Rapid Micro Biosystems' Asset Turnover too high?
Rapid Micro Biosystems' current Asset Turnover is 0.12. Overall, Rapid Micro Biosystems has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rapid Micro Biosystems' Asset Turnover compare to ZOMDF and STIM?
Rapid Micro Biosystems' Asset Turnover of 0.12 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Medical Devices & Instruments company?
A good Asset Turnover depends on the Medical Devices & Instruments industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Rapid Micro Biosystems and its competitors. Rapid Micro Biosystems's current Asset Turnover is 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Micro Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Rapid Micro Biosystems (RPID) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.88, compared to a current price of $1.70 — trading 9.6% below its estimated fair value. The current Asset Turnover is 0.12. Rapid Micro Biosystems' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Rapid Micro Biosystems (RPID), the current Asset Turnover is 0.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rapid Micro Biosystems (RPID) Overvalued in 2026?
Based on GuruFocus' analysis, Rapid Micro Biosystems stock appears to be undervalued.
The current stock price of $1.70 is trading 9.6% below its estimated GF Value™ of $1.88.
GuruFocus considers Rapid Micro Biosystems to be Modestly Undervalued.
Key valuation signals for RPID:
Asset Turnover: 0.12
GF Value™: $1.88 vs. price of $1.70 (9.6% below fair value)
No single metric tells the full story. See the RPID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.
60GF Score
Get the complete analysis for RPID
Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPID has been successfully added to your 
